ALERT CENTER: Advisers to the FDA back COVID19 vaccine from Novavax. Agency must now decide whether to authorize. MORE:
Next, the FDA must decide whether to authorize the vaccine made by latecomer Novavax, a protein vaccine that's made with a more conventional technology than today's U.S. options.
“We do have a problem with vaccine uptake that is very serious in the United States," Marks said. "Anything we can do to get people more comfortable to accept these potentially life-saving products is something that we feel we are compelled to do.” Large studies in the U.S., Mexico and Britain found two doses of the Novavax vaccine were safe and about 90% effective at preventing symptomatic COVID-19. One complication: Those studies were done far earlier in the pandemic, well before more contagious coronavirus variants emerged -- including the omicron mutant and its relatives.
And while the trials showed generally people experienced only mild reactions such as injection-site pain or fatigue, the FDA did highlight a possible concern: six cases of heart inflammation, known as myocarditis, found among the 40,000 people who received the vaccine in studies.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Novavax Covid-19 Vaccine Faces FDA Advisers’ ScrutinyThe outside panel of experts will vote on whether the shot should be authorized, after the agency found it effective but flagged a safety concern.
Baca lebih lajut »
FDA advisers meeting on Novavax, a latecomer in COVID-19 vaccine raceA federal advisory committee will vote on whether regulators should authorize a COVID-19 vaccine made by Novavax. From The New York Times.
Baca lebih lajut »
FDA advisory panel to consider approving fourth COVID-19 vaccine, this one from Maryland's NovavaxDevelopment of the vaccine, from Novavax, a Gaithersburg, Maryland-based company, was started at the same time as others in 2020, but the company struggled to produce its shot in large quantities.
Baca lebih lajut »
FDA advisers back Novavax COVID-19 shots as new US optionNovavax shots are already used in Australia, Canada, parts of Europe and dozens of other countries. But U.S. clearance is a key hurdle for the Maryland-based company.
Baca lebih lajut »
FDA panel greenlights Novavax COVID-19 vaccineFDA's vaccine chief said another choice in the U.S. may entice at least some vaccine holdouts - whatever their reason - to consider rolling up their sleeves. FOX13
Baca lebih lajut »
FDA advisers vote to recommend Novavax Covid-19 vaccineAdvisers signaled interest in making available a vaccine made with a technology different from the messenger RNA shots that have dominated the U.S. immunization arsenal against the disease.
Baca lebih lajut »